AU3290397A - Gastric-retentive oral controlled drug delivery system with enhanced retention properties - Google Patents

Gastric-retentive oral controlled drug delivery system with enhanced retention properties

Info

Publication number
AU3290397A
AU3290397A AU32903/97A AU3290397A AU3290397A AU 3290397 A AU3290397 A AU 3290397A AU 32903/97 A AU32903/97 A AU 32903/97A AU 3290397 A AU3290397 A AU 3290397A AU 3290397 A AU3290397 A AU 3290397A
Authority
AU
Australia
Prior art keywords
gastric
delivery system
drug delivery
controlled drug
retention properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32903/97A
Inventor
John W. Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of AU3290397A publication Critical patent/AU3290397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU32903/97A 1996-06-10 1997-05-29 Gastric-retentive oral controlled drug delivery system with enhanced retention properties Abandoned AU3290397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66358896A 1996-06-10 1996-06-10
US08663588 1996-06-10
PCT/US1997/009245 WO1997047285A1 (en) 1996-06-10 1997-05-29 Gastric-retentive oral controlled drug delivery system with enhanced retention properties

Publications (1)

Publication Number Publication Date
AU3290397A true AU3290397A (en) 1998-01-07

Family

ID=24662476

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32903/97A Abandoned AU3290397A (en) 1996-06-10 1997-05-29 Gastric-retentive oral controlled drug delivery system with enhanced retention properties

Country Status (2)

Country Link
AU (1) AU3290397A (en)
WO (1) WO1997047285A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
FR2784583B1 (en) * 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
ATE323493T1 (en) * 1998-11-02 2006-05-15 Alza Corp CONTROLLED RELEASE OF ANTIDEPRESSANTS
EP1428535A1 (en) * 1998-11-02 2004-06-16 ALZA Corporation Controlled delivery of antidepressants
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
EP1242057A2 (en) * 1999-11-02 2002-09-25 DepoMed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
AU2004204825B2 (en) 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
DE102005011029A1 (en) * 2005-03-08 2006-09-14 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition for peroral application with controlled release of active substances
CA2614885C (en) 2005-07-11 2015-03-17 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US9744142B2 (en) 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20190007106A (en) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
JP6397407B2 (en) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ Sigma receptor ligands for modulating cellular protein homeostasis
CN107184569A (en) 2012-08-09 2017-09-22 迪纳米斯治疗公司 Keep or improve the method for object health, happiness and/or physiological function
KR20150103718A (en) 2013-01-07 2015-09-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for treating cutaneous t cell lymphoma
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2014284267B2 (en) 2013-07-02 2018-05-10 Ecoplanet Environmental Llc Volatile organic compound formulations having antimicrobial activity
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6932506B2 (en) 2013-11-26 2021-09-08 イエール ユニバーシティ Cell permeation composition and method using it
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US9982010B2 (en) 2014-04-07 2018-05-29 Women & Infants Hospital Of Rhode Island 7-dehydrocholesterol derivatives and methods using same
EP3182979B1 (en) 2014-08-20 2023-12-06 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
MX2017014805A (en) 2015-05-19 2018-02-15 Univ Yale Compositions for treating pathological calcification conditions, and methods using same.
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
CN107708701A (en) 2015-06-30 2018-02-16 纽拉德有限公司 Novel control of breathing modulating compound and its preparation and application
JP6970667B2 (en) 2015-10-28 2021-11-24 イエール ユニバーシティ Quinoline amide and its usage
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
WO2017190001A1 (en) 2016-04-29 2017-11-02 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2018027024A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CN109843379B (en) 2016-09-01 2022-12-30 梅比斯发现公司 Substituted ureas and methods of making and using the same
WO2018085619A1 (en) 2016-11-07 2018-05-11 Arbutus Biopharma, Inc. Substituted pyridinone-containing tricyclic compounds, and methods using same
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
EP3612184B1 (en) 2017-04-17 2024-06-05 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
US20210085796A1 (en) 2017-07-28 2021-03-25 Yale University Anticancer drugs and methods of making and using same
KR20200072478A (en) 2017-09-08 2020-06-22 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Compounds, compositions and methods for treatment or prevention of HER-driven drug-resistant cancer
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN111818929A (en) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 Compounds, compositions and methods for treating and/or preventing periodontal disease
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
TW201944989A (en) 2018-01-24 2019-12-01 洛克斐勒大學 Antibacterial compounds, compositions thereof, and methods using same
KR20210015892A (en) 2018-05-29 2021-02-10 세르시 테라퓨틱스 인코포레이티드 Compound for the treatment of pain, composition comprising the same, and method of using the same
CN112839661A (en) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 Inositol phosphates for the treatment of ectopic calcification
TWI827760B (en) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
CA3130735A1 (en) 2019-01-30 2020-08-06 Sanifit Therapeutics, S.A. Inositol phosphate compounds for use in increasing tissular perfusion
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin
US11524048B2 (en) 2019-05-09 2022-12-13 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
KR20230042263A (en) 2020-06-09 2023-03-28 이노자임 파마, 인코포레이티드 Soluble ENPP1 or ENPP3 Proteins and Uses Thereof
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659558A (en) * 1982-03-22 1987-04-21 Alza Corporation Oral delivery system comprising a plurality of tiny pills for delivering drug in the stomach and intestine
JPS6143108A (en) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd Medicinal drug and its preparation
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
EP0391462A1 (en) * 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
DE69017915T2 (en) * 1989-10-26 1995-07-27 Nippon Shinyaku Co Ltd PREPARATION FOR THE STOMACH.
CA2050042A1 (en) * 1990-09-17 1992-03-18 Zola P. Horovitz Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
WO1993018755A1 (en) * 1992-03-25 1993-09-30 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms

Also Published As

Publication number Publication date
WO1997047285A1 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
AU2827095A (en) Controlled release oral drug delivery system
AU3204995A (en) Closed drug delivery system
AU664807B2 (en) Drug delivery system
AU6876498A (en) Intravesical drug delivery system
AU6140598A (en) Multipathway electronically-controlled drug delivery system
AU1719800A (en) Drug delivery systems and methods
AU5676596A (en) Oral insulin delivery
AU1728797A (en) Comforter for delivering medicine
GB2319184B (en) Drug delivery device
AU5914999A (en) Controlled release drug delivery
AU4989993A (en) Drug delivery system
AU4468197A (en) Hyaluronic drug delivery system
AU2816297A (en) Recipient-dosage delivery system
AU2999995A (en) Self-emulsifying drug delivery system
AU2337897A (en) Uniform drug delivery therapy
AU7711098A (en) Drug delivery system
AU7201998A (en) Drug delivery system
AU2377197A (en) Improved drug injection system with self-aspiration feature
AU7454698A (en) Improvement in medicament administration system
AU3837999A (en) Drug delivery device
AU2367900A (en) Chewable drug delivery system
AU2420997A (en) Oligopeptides for drug delivery
AU3481497A (en) Chitosan drug delivery system
AU1671997A (en) Drug delivery system using galactoxyloglucan